Author: Dino Mustafić

Lynparza Reduced Risk of Death by 32% in the Adjuvant Treatment of Patients with Germline BRCA-mutated High-risk Early Breast Cancer
March 16, 2022 Off

Lynparza Reduced Risk of Death by 32% in the Adjuvant Treatment of Patients with Germline BRCA-mutated High-risk Early Breast Cancer

By Dino Mustafić

Further positive results from the OlympiA Phase III trial showed AstraZeneca and MSD’s Lynparza (olaparib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus placebo in the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy.

Sanofi Announces €300 Million Collaboration with Blackstone Life Sciences to Advance an Innovative Treatment for Multiple Myeloma
March 15, 2022 Off

Sanofi Announces €300 Million Collaboration with Blackstone Life Sciences to Advance an Innovative Treatment for Multiple Myeloma

By Dino Mustafić

Sanofi and Blackstone (NYSE: BX) have announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) will contribute up to €300 million to accelerate the global pivotal studies and the clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa, to treat patients with multiple myeloma (MM).

AYOXXA Receives Fresh Capital for Commercial Growth in Europe, US and Asia Led by Prosnav Capital
March 14, 2022 Off

AYOXXA Receives Fresh Capital for Commercial Growth in Europe, US and Asia Led by Prosnav Capital

By Dino Mustafić

AYOXXA Biosystems GmbH has announced the successful closing of a financing round which will provide runway for the coming 3 – 5 years. The round was led by Hong Kong-based strategic investor, Prosnav Capital, who will provide AYOXXA access to the Asian market with a broad regional network. Besides Prosnav, a group of existing shareholders participated in the financing.